fellutamide B: a neurotrophic lipopeptide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9829143 |
| CHEMBL ID | 265252 |
| MeSH ID | M0501952 |
| Synonym |
|---|
| (2s)-2-[[(2s)-4-amino-2-[[(3r)-3-hydroxydodecanoyl]amino]-4-oxo-butanoyl]amino]-n-[(1s)-1-formyl-3-methyl-butyl]pentanediamide |
| fellutamide b |
| n2-[(3r)-3-hydroxydodecanoyl]-l-asparaginyl-n1-[(2s)-4-methyl-1-oxopentan-2-yl]-l-glutamamide |
| CHEMBL265252 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID268220 | Cytotoxicity against rat PC12 cell line by [3H] thymidine incorporation assay | 2006 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14 | Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog. |
| AID268221 | Cytotoxicity against mouse LM cell line by [3H] thymidine incorporation assay | 2006 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14 | Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog. |
| AID268222 | Induction of NGF secretion in LM cells at 50 uM after 24 hrs | 2006 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14 | Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog. |
| AID268219 | Cytotoxicity against human KB cell line by [3H] thymidine incorporation assay | 2006 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14 | Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||